ID   OV-1063
AC   CVCL_4366
SY   Ov-1063; OV 1063; OV1063; 0V-1063
DR   ATCC; CRL-2183
DR   BioSample; SAMN03152024
DR   BioSample; SAMN03472561
DR   cancercelllines; CVCL_4366
DR   CCRID; 1101HUM-PUMC000361
DR   ChEMBL-Cells; CHEMBL3308411
DR   ChEMBL-Targets; CHEMBL614211
DR   Cosmic; 844352
DR   Cosmic; 849609
DR   Cosmic; 897432
DR   Cosmic; 948286
DR   Cosmic; 1044238
DR   Cosmic; 2582808
DR   Cosmic; 2674700
DR   PubChem_Cell_line; CVCL_4366
DR   Wikidata; Q54936820
RX   PubMed=2412195;
RX   PubMed=9698466;
RX   PubMed=11103784;
RX   PubMed=11565033;
RX   PubMed=20143388;
RX   PubMed=25846456;
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Partially misidentified. The stock formerly distributed by ATCC and CCRID was misidentified and was actually DU145 (Cellosaurus=CVCL_0105). This is not the case of the original stock from Hadassah Medical Center.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00340.
CC   Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Glu40Ter (c.118G>T); Zygosity=Unspecified (PubMed=11565033).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Lys715Ter (c.2143A>T); ClinVar=VCV001786615; Zygosity=Unspecified (PubMed=25846456).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val274Phe (c.820G>T); ClinVar=VCV000376674; Zygosity=Unspecified (PubMed=25846456).
CC   Omics: Transcriptome analysis by serial analysis of gene expression (SAGE).
CC   Miscellaneous: STR profile from personal communication of Granit A., Hadassah Medical Center, Jerusalem, Israel.
CC   Discontinued: ATCC; CRL-2183; true.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): Direct_author_submission
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D10S1248: 16,17
ST   D12S391: 23
ST   D13S317: 12
ST   D16S539: 10,13
ST   D18S51: 17,20
ST   D19S433: 13,16.2
ST   D1S1656: 14,15.3
ST   D21S11: 31,32.2
ST   D22S1045: 16
ST   D2S1338: 17
ST   D2S441: 10,14
ST   D3S1358: 16,17
ST   D5S818: 11,12
ST   D7S820: 10,14
ST   D8S1179: 9,14
ST   FGA: 20
ST   Penta D: 12,15
ST   Penta E: 7,16
ST   TH01: 9.3
ST   TPOX: 11
ST   vWA: 15,17
DI   NCIt; C5228; Ovarian cystadenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   57Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 26
//
RX   PubMed=2412195; DOI=10.1159/000226056;
RA   Horowitz A.T., Treves A.J., Voss R., Okon E., Fuks Z., Davidson L.,
RA   Biran S.;
RT   "A new human ovarian carcinoma cell line: establishment and analysis
RT   of tumor-associated markers.";
RL   Oncology 42:332-337(1985).
//
RX   PubMed=9698466; DOI=10.1006/gyno.1998.5039;
RA   Maxwell G.L., Risinger J.I., Tong B., Shaw H., Barrett J.C.,
RA   Berchuck A., Futreal P.A.;
RT   "Mutation of the PTEN tumor suppressor gene is not a feature of
RT   ovarian cancers.";
RL   Gynecol. Oncol. 70:13-16(1998).
//
RX   PubMed=11103784;
RA   Hough C.D., Sherman-Baust C.A., Pizer E.S., Montz F.J., Im D.D.,
RA   Rosenshein N.B., Cho K.R., Riggins G.J., Morin P.J.;
RT   "Large-scale serial analysis of gene expression reveals genes
RT   differentially expressed in ovarian cancer.";
RL   Cancer Res. 60:6281-6287(2000).
//
RX   PubMed=11565033; DOI=10.1038/35095068;
RA   Moberg K.H., Bell D.W., Wahrer D.C.R., Haber D.A., Hariharan I.K.;
RT   "Archipelago regulates cyclin E levels in Drosophila and is mutated in
RT   human cancer cell lines.";
RL   Nature 413:311-316(2001).
//
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
//
RX   PubMed=25846456; DOI=10.3892/ijo.2015.2951;
RA   Takenaka M., Saito M., Iwakawa R., Yanaihara N., Saito M., Kato M.,
RA   Ichikawa H., Shibata T., Yokota J., Okamoto A., Kohno T.;
RT   "Profiling of actionable gene alterations in ovarian cancer by
RT   targeted deep sequencing.";
RL   Int. J. Oncol. 46:2389-2398(2015).
//